Statin-CYP3A4 Inhibitor Concomitancy Shows Non-Differential Risk for Adverse Events Based on Statin Metabolism

Aug-09

AUTHORS : Prof Christopher G. Rowan (Details for study: Upenn) now works at COHRDATA, INC, San Clemente, CA, US / Institute for Health, Health Care Policy, and Aging Research at Rutgers, 112 Paterson St New Brunswick, NJ 08901 – Email: crowan@cohrdata.com – Profile: https://pets.rutgers.edu/people/christopher-rowan/ AND http://www.cohrdata.com/about-us

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 18(S1):6-7

DOI : 10.1002/pds.1806

Statin-CYP3A4 Inhibitor Concomitancy Shows Non-Differential Risk for Adverse Events Based on Statin Metabolism

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study